Whether confirmed in humans, the combined use of CXCR2/PD-1 inhibitors might represent a successful strategy to improve NASH-related HCC therapy by restoring cancer immunosurveillance. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.